A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Rivastigmine (Primary)
- Indications Dementia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Jul 2017 Planned End Date changed from 31 Aug 2018 to 30 Nov 2018.
- 22 Jul 2017 Planned primary completion date changed from 31 Aug 2018 to 30 Nov 2018.
- 22 Jul 2017 Planned initiation date changed from 31 May 2017 to 31 Dec 2017.